Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic lymphatic leukemia]

K Lechner1, S Bilbeisi, E Wittmann

  • 1Abteilung Hämatologie/Hämostaseologie, Universität Wien.

Wiener Klinische Wochenschrift
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of patients' needs and doctors' perceptions of information requirements related to a diagnosis of oesophageal or gastric cancer.

European journal of cancer care·2010
Same author

High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival.

Annals of hematology·2003
Same author

Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.

Annals of hematology·2003
Same author

Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia.

Annals of hematology·2003
Same author

Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation.

Annals of hematology·2003
Same author

Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation.

Bone marrow transplantation·2002
Same journal

[Vaccination of immunocompromised individuals: Expert opinion - update 2026].

Wiener klinische Wochenschrift·2026
Same journal

Systematic review of clinical evidence for Kneipp medicine.

Wiener klinische Wochenschrift·2026
Same journal

Pelvic resections in primary sarcomas : Surgical outcomes and survival analysis of 75 patients.

Wiener klinische Wochenschrift·2026
Same journal

Jungmediziner*innen am Start: 11. Workshop für den medizinischen Nachwuchs.

Wiener klinische Wochenschrift·2026
Same journal

Stellungnahme der ÖGP zur geplanten Gesetzesnovelle zum Nichtraucherschutzgesetz.

Wiener klinische Wochenschrift·2026
Same journal

MUW researcher of the month: Dr. Moritz Schaefer.

Wiener klinische Wochenschrift·2026
See all related articles

Chronic lymphocytic leukemia (B-CLL) diagnosis relies on specific cell markers and disease stage. Treatment varies by stage, with bone marrow transplant offering potential cures for select advanced cases.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Context:

  • Chronic lymphocytic leukemia of the B-cell type (B-CLL) is the most prevalent leukemia.
  • Diagnosis involves sustained lymphocytosis, bone marrow involvement, and CD19/CD5 positive cells.
  • Disease stage and lymphocyte doubling time are key prognostic indicators.

Purpose:

  • To outline diagnostic criteria for B-CLL.
  • To review current and emerging treatment strategies for B-CLL based on disease stage.
  • To discuss the role of novel agents and bone marrow transplantation.

Summary:

  • Early-stage B-CLL often requires no immediate treatment.
  • Stage A (active disease) and B patients are typically treated with chlorambucil/prednisone, though optimal regimens are under investigation.

Related Experiment Videos

  • Stage C patients may benefit from anthracycline-based therapies.
  • Nucleoside analogues like fludarabine and cladribine show efficacy in refractory cases and are being evaluated for frontline therapy.
  • Allogeneic or autologous bone marrow transplantation offers a chance for long-term remission or cure in younger patients with advanced disease.

    • Impact:

    • Informs clinical decision-making for B-CLL patient management.
    • Highlights the evolving treatment landscape for B-CLL.
    • Emphasizes the potential of bone marrow transplantation for cure in specific patient populations.